The biotechnology company has seen one positive revision in the past one month, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for Cytokinetics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Cytokinetics currently carries a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Investors interested in the biotechnology industry may also consider other well-placed stocks such as Affymetrix Inc. (AFFX), Agenus Inc. (AGEN) and AMAG Pharmaceuticals, Inc. (AMAG). All these stocks carry the same Zacks Rank as Cytokinetics.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment